Experience

ImmuneOnco Biopharmaceuticals – HK$319 Million IPO

September 5, 2023

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Los Angeles Santa Monica
Francis Wheeler
Partner, Colorado
Eric Blanchard
Partner, New York
Yiying Wang
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Yunxiang Xu
Associate, Shanghai
Xiaoyu Xu
Associate, Beijing
Cecilia Bai
Associate , Singapore
Rick Jantz
Associate, Los Angeles Santa Monica
Cindy Pan
International Legal Project Manager, Hong Kong
Alex Wu
International Legal Project Manager, Shanghai
Iris Yang
Senior Legal Assistant, Shanghai
Zhengyang Li
Senior Legal Assistant, Hong Kong

Related Practices & Industries

Laekna Announces Largest 18A IPO Year to Date at HK$791 Million

June 29, 2023

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Tonny Yu
Associate, Hong Kong
Xiaoyu Xu
Associate, Beijing
April Wang
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong
Iris Yang
Senior Legal Assistant, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Zhengyang Li
Senior Legal Assistant, Hong Kong

Related Practices & Industries

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Xiaozhen (Shawn) Yu
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

Zion Pharma Announces Sale of Lead Program to Roche

May 15, 2023

Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Aaron Pomeroy
Partner, Colorado
David Burns
Special Counsel, Washington, DC
Xiaoyu Xu
Associate, Beijing
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

InnoRNA Collaboration with BeiGene

July 7, 2022

Cooley advised InnoRNA in its worldwide strategic collaboration with BeiGene to leverage InnoRNA’s innovative technology platform for developing mRNA-based therapeutics. Under the terms of the agreement, InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs. BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene. Financials were not publicly disclosed.

Related contacts

Marya Postner
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing

Related Practices & Industries

View more